Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

Form SCHEDULE 13D Braveheart Bio, Inc. Filed by: ORBIMED ADVISORS LLC Aug 18, 2026 05:00PM

Form SCHEDULE 13D BlossomHill Therapeutics Filed by: ORBIMED ADVISORS LLC Aug 18, 2026 04:53PM

Form SCHEDULE 13G/A Whitehawk Therapeutics, Filed by: ORBIMED ADVISORS LLC Aug 14, 2026 05:59PM

Form SCHEDULE 13G/A Vistagen Therapeutics, Filed by: ORBIMED ADVISORS LLC Aug 14, 2026 05:52PM

Form SCHEDULE 13G SPRUCE BIOSCIENCES, INC. Filed by: ORBIMED ADVISORS LLC Aug 14, 2026 05:49PM

View Older Stories

Aug 14, 2026 05:44PM Form SCHEDULE 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC
Aug 14, 2026 05:40PM Form SCHEDULE 13G Lexeo Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 14, 2026 05:35PM Form SCHEDULE 13G IMMUNIC, INC. Filed by: ORBIMED ADVISORS LLC
Aug 14, 2026 05:30PM Form SCHEDULE 13G/A Forte Biosciences, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 14, 2026 04:11PM Form 13F-HR ORBIMED ADVISORS LLC For: Jun 30
Aug 12, 2026 04:44PM Form 4 BlossomHill Therapeutics For: Aug 10 Filed by: ORBIMED ADVISORS LLC
Aug 10, 2026 04:44PM Form SCHEDULE 13D/A MBX Biosciences, Inc. Filed by: ORBIMED ADVISORS LLC
Aug 6, 2026 09:09PM Form 3 BlossomHill Therapeutics For: Aug 06 Filed by: ORBIMED ADVISORS LLC
Aug 5, 2026 09:19PM Form 3 Braveheart Bio, Inc. For: Aug 05 Filed by: ORBIMED ADVISORS LLC
Aug 5, 2026 09:08PM Form SCHEDULE 13D Yarrow Bioscience, Inc. Filed by: ORBIMED ADVISORS LLC
Jul 29, 2026 09:27PM Form 3 Yarrow Bioscience, Inc. For: Jul 27 Filed by: ORBIMED ADVISORS LLC
Jul 29, 2026 06:47PM Form 4 Scribe Therapeutics, For: Jul 27 Filed by: ORBIMED ADVISORS LLC
Jul 29, 2026 06:42PM Form SCHEDULE 13D Scribe Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jul 23, 2026 09:33PM Form 3 Scribe Therapeutics, For: Jul 23 Filed by: ORBIMED ADVISORS LLC
Jul 20, 2026 09:33PM Form SCHEDULE 13D/A Q32 Bio Inc. Filed by: ORBIMED ADVISORS LLC
Jul 9, 2026 04:44PM Form 4 Sionna Therapeutics, For: Jul 07 Filed by: ORBIMED ADVISORS LLC
Jul 2, 2026 04:42PM Form 4 Sionna Therapeutics, For: Jun 30 Filed by: ORBIMED ADVISORS LLC
Jun 30, 2026 08:45AM Dogwood Therapeutics names Iain Dukes to lead new advisory board
Jun 24, 2026 07:16PM Form SCHEDULE 13D/A Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jun 22, 2026 08:13PM Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jun 22, 2026 08:11PM Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jun 17, 2026 07:42PM Form SCHEDULE 13D/A Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jun 17, 2026 06:59PM Biogen to acquire RayThera for up to $1 billion
Jun 15, 2026 09:21PM Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jun 15, 2026 09:19PM Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
Jun 15, 2026 06:10PM Form SCHEDULE 13D/A Shattuck Labs, Inc. Filed by: ORBIMED ADVISORS LLC
Jun 9, 2026 08:58PM Form 4 Shattuck Labs, Inc. For: Jun 08 Filed by: ORBIMED ADVISORS LLC
Jun 1, 2026 09:13PM Form 4 Q32 Bio Inc. For: May 28 Filed by: ORBIMED ADVISORS LLC
Jun 1, 2026 09:10PM Form SCHEDULE 13D/A Q32 Bio Inc. Filed by: ORBIMED ADVISORS LLC
Jun 1, 2026 12:39PM Form 144/A Sionna Therapeutics, Filed by: ORBIMED ADVISORS LLC
May 29, 2026 08:57PM Form 4 Sionna Therapeutics, For: May 27 Filed by: ORBIMED ADVISORS LLC
May 29, 2026 06:44PM Form 144 Sionna Therapeutics, Filed by: ORBIMED ADVISORS LLC
May 15, 2026 04:45PM Form SCHEDULE 13G Xilio Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
May 15, 2026 04:43PM Form SCHEDULE 13G/A RAPT Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
May 15, 2026 04:41PM Form SCHEDULE 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC
May 15, 2026 04:41PM Form SCHEDULE 13G/A Forte Biosciences, Inc. Filed by: ORBIMED ADVISORS LLC
May 15, 2026 04:41PM Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
May 15, 2026 04:40PM Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
May 11, 2026 06:59PM Form 4 Sionna Therapeutics, For: May 07 Filed by: ORBIMED ADVISORS LLC
May 6, 2026 05:48PM Form SCHEDULE 13D/A Q32 Bio Inc. Filed by: ORBIMED ADVISORS LLC
May 5, 2026 06:56PM Form SCHEDULE 13D/A Traws Pharma, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 29, 2026 07:07PM Form SCHEDULE 13D/A ImageneBio, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 28, 2026 09:42PM Form 4 Traws Pharma, Inc. For: Apr 16 Filed by: ORBIMED ADVISORS LLC
Apr 23, 2026 08:43PM Form SCHEDULE 13D/A Prelude Therapeutics Filed by: ORBIMED ADVISORS LLC
Apr 23, 2026 06:56PM Form 4 Prelude Therapeutics For: Apr 21 Filed by: ORBIMED ADVISORS LLC
Apr 21, 2026 08:40PM Form 4 Sionna Therapeutics, For: Apr 17 Filed by: ORBIMED ADVISORS LLC
Apr 20, 2026 06:46PM Form SCHEDULE 13D/A Sionna Therapeutics, Filed by: ORBIMED ADVISORS LLC
Apr 16, 2026 07:04PM Form 4 Sionna Therapeutics, For: Apr 14 Filed by: ORBIMED ADVISORS LLC
Apr 10, 2026 08:28PM Form SCHEDULE 13D/A Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 9, 2026 05:35PM Form 144 Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC

View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed